Patents by Inventor Dorothea Sizmann
Dorothea Sizmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10041134Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid of HCV in a sample, wherein an amplification of the nucleic acids in said sample is carried out. This amplification involves a polymerase, primers for generating an amplicon and at least two detectable probes specific for different sequence portions of said amplicon. Detection of the obtained amplicon is brought about by detecting hybridization of the probes mentioned above to said different sequence portions of the amplicon. The invention further provides reaction mixtures and kits for amplifying and detecting a target nucleic acid of HCV involving the use of at least two detectable probes specific for different sequence portions of an amplicon.Type: GrantFiled: October 13, 2016Date of Patent: August 7, 2018Assignee: Roche Molecular Systems, Inc.Inventors: Frank Bergmann, Dorothea Sizmann, Heike Zitzer
-
Patent number: 9963737Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid in a sample, said target nucleic comprising subgroups with sequence variations and/or individual mutations, wherein an amplification of the nucleic acids in said sample is carried out. This amplification involves a polymerase, primers for generating an amplicon and at least two detectable probes specific for different sequence portions of said amplicon. Detection of the obtained amplicon is brought about by detecting hybridization of the probes mentioned above to said different sequence portions of the amplicon. The invention further provides reaction mixtures and kits for amplifying and detecting a target nucleic acid comprising subgroups with sequence variations and/or individual mutations involving the use of at least two detectable probes specific for different sequence portions of an amplicon.Type: GrantFiled: October 16, 2013Date of Patent: May 8, 2018Assignee: Roche Molecular Systems, Inc.Inventors: Frank Bergmann, Dorothea Sizmann, Heike Zitzer
-
Publication number: 20170292145Abstract: The present invention relates to new methods and uses for the qualitative and quantitative detection of microbial nucleic acids using at least a first control nucleic acid, or a first and a second control nucleic acid in different concentrations. The method is based on amplification of nucleic acids, for example the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses.Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Inventors: Reiner Babiel, Frank Bergmann, Dorothea Sizmann
-
Patent number: 9719133Abstract: The present invention relates to new methods and uses for the qualitative and quantitative detection of microbial nucleic acids using at least a first control nucleic acid, or a first and a second control nucleic acid in different concentrations. The method is based on amplification of nucleic acids, for example the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses.Type: GrantFiled: September 26, 2014Date of Patent: August 1, 2017Assignee: Roche Molecular Systems, Inc.Inventors: Reiner Babiel, Frank Bergmann, Dorothea Sizmann
-
Publication number: 20170088907Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid of HCV in a sample, wherein an amplification of the nucleic acids in said sample is carried out. This amplification involves a polymerase, primers for generating an amplicon and at least two detectable probes specific for different sequence portions of said amplicon. Detection of the obtained amplicon is brought about by detecting hybridization of the probes mentioned above to said different sequence portions of the amplicon. The invention further provides reaction mixtures and kits for amplifying and detecting a target nucleic acid of HCV involving the use of at least two detectable probes specific for different sequence portions of an amplicon.Type: ApplicationFiled: October 13, 2016Publication date: March 30, 2017Inventors: Frank Bergmann, Dorothea Sizmann, Heike Zitzer
-
Patent number: 9512494Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid of HCV in a sample, wherein an amplification of the nucleic acids in said sample is carried out. This amplification involves a polymerase, primers for generating an amplicon and at least two detectable probes specific for different sequence portions of said amplicon. Detection of the obtained amplicon is brought about by detecting hybridization of the probes mentioned above to said different sequence portions of the amplicon. The invention further provides reaction mixtures and kits for amplifying and detecting a target nucleic acid of HCV involving the use of at least two detectable probes specific for different sequence portions of an amplicon.Type: GrantFiled: October 16, 2013Date of Patent: December 6, 2016Assignee: Roche Molecular Systems, Inc.Inventors: Frank Bergmann, Dorothea Sizmann, Heike Zitzer
-
Patent number: 9447476Abstract: The present invention is directed to improved methods for amplifying and detecting a nucleic acid target that may be present in a biological sample comprising a primer pair for generating an amplicon, wherein at least one primer is modified at the 5? terminus with a polyN sequence being non-complementary to the target sequence, and a detectable probe specific for said amplicon or a DNA binding dye. The formation of high molecular weight products during amplification is prevented or partly or completely suppressed. The invention further provides reaction mixtures and kits comprising said primers for preventing or suppressing the formation of high molecular weight products during amplification and detection of the nucleic acid target.Type: GrantFiled: October 16, 2013Date of Patent: September 20, 2016Assignee: Roche Molecular Systems, Inc.Inventors: Reiner Babiel, Frank Bergmann, Dorothea Sizmann
-
Publication number: 20150017645Abstract: The present invention relates to new methods and uses for the qualitative and quantitative detection of microbial nucleic acids using at least a first control nucleic acid, or a first and a second control nucleic acid in different concentrations. The method is based on amplification of nucleic acids, for example the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses.Type: ApplicationFiled: September 26, 2014Publication date: January 15, 2015Inventors: Reiner Babiel, Frank Bergmann, Dorothea Sizmann
-
Publication number: 20140134611Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid in a sample, said target nucleic comprising subgroups with sequence variations and/or individual mutations, wherein an amplification of the nucleic acids in said sample is carried out. This amplification involves a polymerase, primers for generating an amplicon and at least two detectable probes specific for different sequence portions of said amplicon. Detection of the obtained amplicon is brought about by detecting hybridization of the probes mentioned above to said different sequence portions of the amplicon. The invention further provides reaction mixtures and kits for amplifying and detecting a target nucleic acid comprising subgroups with sequence variations and/or individual mutations involving the use of at least two detectable probes specific for different sequence portions of an amplicon.Type: ApplicationFiled: October 16, 2013Publication date: May 15, 2014Applicant: ROCHE MOLECULAR SYSTEM, INC.Inventors: Frank Bergmann, Dorothea Sizmann, Heike Zitzer
-
Publication number: 20140127673Abstract: The present invention relates to a method for amplifying and detecting a target nucleic acid of HCV in a sample, wherein an amplification of the nucleic acids in said sample is carried out. This amplification involves a polymerase, primers for generating an amplicon and at least two detectable probes specific for different sequence portions of said amplicon. Detection of the obtained amplicon is brought about by detecting hybridization of the probes mentioned above to said different sequence portions of the amplicon. The invention further provides reaction mixtures and kits for amplifying and detecting a target nucleic acid of HCV involving the use of at least two detectable probes specific for different sequence portions of an amplicon.Type: ApplicationFiled: October 16, 2013Publication date: May 8, 2014Applicant: Roche Molecular System, Inc.Inventors: Frank Bergmann, Dorothea Sizmann, Heike Zitzer
-
Publication number: 20140113279Abstract: The present invention is directed to improved methods for amplifying and detecting a nucleic acid target that may be present in a biological sample comprising a primer pair for generating an amplicon, wherein at least one primer is modified at the 5? terminus with a polyN sequence being non-complementary to the target sequence, and a detectable probe specific for said amplicon or a DNA binding dye. The formation of high molecular weight products during amplification is prevented or partly or completely suppressed. The invention further provides reaction mixtures and kits comprising said primers for preventing or suppressing the formation of high molecular weight products during amplification and detection of the nucleic acid target.Type: ApplicationFiled: October 16, 2013Publication date: April 24, 2014Applicant: ROCHE MOLECULAR SYSTEM, INC.Inventors: Reiner Babiel, Frank Bergmann, Dorothea Sizmann
-
Publication number: 20100041040Abstract: The present invention relates to new methods and uses for the detection and quantification of microbial nucleic acids employing an internal quantitative reference. Preferred methods are based on the amplification of nucleic acids, preferably the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses. Moreover, an analytical system for advantageously performing the method according to the invention is disclosed.Type: ApplicationFiled: June 5, 2009Publication date: February 18, 2010Applicant: ROCHE MOLECULAR SYSTEMS, INC.Inventors: Reiner Babiel, Joachim Glaubitz, Lutz Guertler, Dorothea Sizmann, Karen K.Y. Young
-
Patent number: 7244575Abstract: The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein-(or transmembrane glycoprotein)-chaperone complex and the advantageous use of a chaperone-antigen complex especially in the detection of antibodies to HIV in immunoassays, preferably according to the double antigen bridge concept, or as an immunogen. The invention also discloses soluble complexes comprising a variant of HIV-1 gp41 or a variant of HIV-2 gp36, respectively, and a chaperone selected from the peptidyl-prolyl-isomerase class of chaperones. Variants comprising specific amino-acid substitutions in the N-helical domain of HIV-1 gp41 or of HIV-2 gp36, respectively, are also described.Type: GrantFiled: March 24, 2005Date of Patent: July 17, 2007Assignee: Roche Diagnostics CorporationInventors: Christian Scholz, Herbert Andres, Elke Faatz, Alfred Engel, Dorothea Sizmann
-
Patent number: 6962982Abstract: The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein- (or transmembrane glycoprotein)-chaperone complex and the advantageous use of a chaperone-antigen complex especially in the detection of antibodies to HIV in immunoassays, preferably according to the double antigen bridge concept, or as an immunogen. The invention also discloses soluble complexes comprising a variant of HIV-1 gp41 or a variant of HIV-2 gp36, respectively, and a chaperone selected from the peptidyl-prolyl-isomerase class of chaperones. Variants comprising specific amino-acid substitutions in the N-helical domain of HIV-1 gp41 or of HIV-2 gp36, respectively, are also described.Type: GrantFiled: June 24, 2002Date of Patent: November 8, 2005Assignee: Roche Diagnostics CorporationInventors: Christian Scholz, Herbert Andres, Elke Faatz, Alfred Engel, Dorothea Sizmann
-
Publication number: 20050181358Abstract: The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein-(or transmembrane glycoprotein)-chaperone complex and the advantageous use of a chaperone-antigen complex especially in the detection of antibodies to HIV in immunoassays, preferably according to the double antigen bridge concept, or as an immunogen. The invention also discloses soluble complexes comprising a variant of HIV-1 gp41 or a variant of HIV-2 gp36, respectively, and a chaperone selected from the peptidyl-prolyl-isomerase class of chaperones. Variants comprising specific amino-acid substitutions in the N-helical domain of HIV-1 gp41 or of HIV-2 gp36, respectively, are also described.Type: ApplicationFiled: March 24, 2005Publication date: August 18, 2005Inventors: Christian Scholz, Herbert Andres, Elke Faatz, Alfred Engel, Dorothea Sizmann
-
Publication number: 20030176665Abstract: The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein- (or transmembrane glycoprotein)-chaperone complex and the advantageous use of a chaperone-antigen complex especially in the detection of antibodies to HIV in immunoassays, preferably according to the double antigen bridge concept, or as an immunogen. The invention also discloses soluble complexes comprising a variant of HIV-1 gp41 or a variant of HIV-2 gp36, respectively, and a chaperone selected from the peptidyl-prolyl-isomerase class of chaperones. Variants comprising specific amino-acid substitutions in the N-helical domain of HIV-1 gp41 or of HIV-2 gp36, respectively, are also described.Type: ApplicationFiled: June 24, 2002Publication date: September 18, 2003Inventors: Christian Scholz, Herbert Andres, Elke Faatz, Alfred Engel, Dorothea Sizmann